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Abstract
Liver transplantation is the treatment of choice for end 
stage liver disease, but availability of liver grafts is still 
the main limitation to its wider use. Extended criteria 
donors (ECD) are considered not ideal for several 
reasons but their use has dramatically grown in the 
last decades in order to augment the donor liver pool. 
Due to improvement in surgical and medical strategies, 
results using grafts from these donors have become 
acceptable in terms of survival and complications; 
nevertheless a big debate still exists regarding their 
selection, discharge criteria and allocation policies. 
Many studies analyzed the use of these grafts from 
many points of view producing different or contradictory 
results so that accepted guidelines do not exist and the 
use of these grafts is still related to non-standardized 
policies changing from center to center. The aim of 
this review is to analyze every step of the donation-
transplantation process emphasizing all those strategies, 
both clinical and experimental, that can optimize results 
using ECD.
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Core tip: This review analyzes the donation-trans-
plantation process when using extended criteria donors. 
Every step, from donor selection to transplantation, 
is discussed emphasizing experimental and clinical 
strategies that can lead to optimize results. 
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INTRODUCTION
Liver transplantation (LT) is the treatment of choice 
for patients with end stage liver disease. Due to 
improvement in surgical techniques, immunosuppressive 
strategies, and patient management, the number of 
candidates has dramatically grown in the last decades 
while the number of donors has remained stable. This 
gap has stimulated the development of innovative 
strategies to increase the donor pool. Currently, the 
ideal liver donor - younger than 40 years; trauma as 
the cause of death; donation after brain death; hemo-
dynamic stability; without macrovescicular steatosis, 
infection(s) or chronic liver disease[1] - is less frequent 
due to demographic changes in the general population[2]. 
The concept of extended criteria donors (ECD) was 
introduced to indicate donors associated with a higher 
risk of primary non function (PNF) of the liver graft, 
delayed graft function (DGF), and a poorer prognosis 
after transplantation. Elderly donors (> 60 years), 
donors with malignancies, infections, macrovescicular 
steatosis > 30%, donors after cardiac death (DCD), 
hypernatremia, hemodynamic instability, prolonged 
cold ischemia time (CIT), split liver grafts, and living 
donor liver transplants (LDLT) are all included in this 
category[3-5].
Despite numerous studies, the impact of each 
donor variable on recipient outcome is still debated 
due to controversial results. Some authors reported 
that careful liver graft selection provides comparable 
results vs optimal donor grafts, and some recent studies 
confirm these findings[4-5]. Nevertheless, the reported 
results may be related to specific donor demographic 
characteristics (i.e., healthier life styles) or to the 
experience of transplant teams with management of 
these donors[6]. The aim of the present review is to 
appraise all strategies that can be implemented in view 
of optimization of use of ECD in LT.
DONOR EVALUATION
Age
Old donors should be carefully evaluated as age is 
related to allograft failure and post-transplant death[7]. 
Nevertheless, the progressive aging of the population 
and the decreasing incidence of trauma-related deaths 
have made elderly donors a considerable resource in 
many countries. In our recent study the mean donor age 
was 70 years[5], and similar results were reported by the 
Spanish liver donor registry[8]. Old organs develop brown 
atrophy, show a decrease in weight and number of 
cells, thickening of endothelial cell lining, endothelial cell 
fenestrations, reduction of blood flow, reduced synthetic 
capacity resulting in a diminished response to external 
stressors and a limited regeneration rate[9-13]. Short term 
complications using these grafts include PNF - defined 
as an irreversible graft dysfunction requiring liver re-
transplantation within 10 d - initial poor function (IPF) 
and vascular complications[14]. Long-term complications 
include reduced patient and graft survival, especially 
in HCV positive recipients, and ischemic type biliary 
lesions (ITBL)[14]. These grafts are extremely sensitive 
to hemodynamic instability, and an appropriate donor 
management is pivotal with adequate systemic blood 
(> 100 mmHg) and central venous pressures (> 10 cm 
H2O), a hematocrit > 25%, normal body temperature, 
and diuresis greater than 1 mL/kg per hour in order to 
avoid hypoperfusion and low oxygen support to the liver 
graft[15]. A rapid procurement technique with minimal 
organ manipulation and double perfusion (aortic and 
portal) should be preferred[15]. In order to minimize the 
ischemia/reperfusion injury (I/R), CIT should be as short 
as possible[14,15]. Many series using graft older than 70 
years showed optimal results when CIT is shorter than 
8 h, whilst a CIT > 12 h is associated with a twofold risk 
of graft failure[16]. Thus, procurement in distant hospitals 
should be carefully evaluated and allocation to more 
stable patients who can better tolerate some degree of 
organ dysfunction should be warranted[16,17]. Older liver 
grafts are preferentially allocated to low biochemical 
model for end-stage (MELD) score patients and HCV-
negative recipients with hepatocarcinoma[5,15].
Hemodynamic instability
Previous United Network for Organ Sharing (UNOS) 
data have shown that organs subjected to prolonged 
hypotension do not show any significant increase in post-
transplant graft loss[17]. However, graft loss increased 
in transplants from donors receiving norepinephrine[17]. 
Some studies showed that dopamine dose > 10 µg/kg 
per minute[18], or 6 µg/kg per minute[19] had a significant 
impact on early graft function. Systemic blood pressure 
should be kept above 90-100 mmHg as low pressure is 
related to increased preservation injury[20]. The use of 
dopamine is indicated to increase the mesenteric and 
renal flows at doses of 2-5 µg/kg per minute. Higher 
doses can lead to renal impairment and a dopamine 
dose > 15 µg/kg per minute is considered a marginality 
criterion[21,22].
Hypernatremia
Hypernatremia is considered a risk factor for graft 
dysfunction, but the mechanism of hypernatremia-related 
injury to liver cells is not clear[23,24]. One hypothesis 
is that a sudden change in extracellular osmolality 
in a liver graft obtained from a hypernatremic donor 
might cause intracellular water accumulation and cell 
swelling[25]. However, high serum sodium concentrations 
may promote accumulation of osmoles within the liver 
allograft cells. Subsequent transplantation of these livers 
into recipients with normal serum sodium levels may 
promote intracellular water accumulation, hepatocyte 
lyses, and death[23]. Avolio et al[23] suggested that donor 
hypernatremia may adversely affect the outcome of LT 
and showed a direct correlation between the donor serum 
sodium concentrations and the recipient liver enzyme 
levels [aspartate aminotransferase (AST) and alanina 
aminotransferase (ALT)] after surgery[23]. González 
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et al[24] showed that donor hypernatremia correlates 
with hepatic allograft dysfunction, whilst Figueras et 
al[25] reported that donor hypernatremia is associated 
with high bilirubin levels post-operatively and graft loss 
within the first month post-transplantation. Totsuka et 
al[26] showed that both graft function and survival were 
improved by correction of donor hypernatremia and 
suggested that latent changes in hepatocytes induced by 
hypernatremia are reversible and might be attenuated 
by appropriate donor management. Recent studies have 
found that donor hypernatremia does not affect graft 
survival in liver and kidney transplantation[27]. 
Infections
Hepatitis B virus: In the presence of antibody to 
hepatitis B core antigen (anti-HBc) IgM-positivity or 
circulating hepatitis B virus (HBV)-DNA levels, some 
centers decline using these organs for donation. Anti-
HBc IgG-positive donor grafts can be safely used, 
provided use of anti-HBV prophylaxis with oral antiviral 
agents in HBV naïve recipients[28-30]. The addition of 
anti-hepatitis B surface antigen immunoglobulin does 
not seem to provide superior protection rates vs oral 
antivirals alone[29].
In pediatric transplantation, organs from anti-HBc-
positive donors are still used with caution after an 
individualized risk-to-benefit evaluation[28-30].
Hepatitis C virus: The use of hepatitis C virus (HCV)-
positive donors for LT was originally debated and not 
widely practiced due to concerns about an increased risk 
of HCV-related graft failure after transplantation[31-34]. 
In the last decade, long-term follow-up data confirmed 
that use of HCV-positive donor grafts in HCV-positive 
recipients was safe and did not affect graft survival[31]. 
In this setting, post-transplant HCV recurrence rates 
were 55.54% vs 41.74% for recipients of HCV-negative 
grafts[32]. Patient and graft survival at 4 years post-
transplantation are similar in recipients of either HCV-
positive or HCV-negative liver grafts[32].
A recent UNOS-based study on 1695 HCV patients 
transplanted with HCV-positive grafts has confirmed no 
difference in patient and graft survival vs HCV-positive 
recipients transplanted with HCV-negative liver grafts[33]. 
An European, multicenter study has also shown similar 
overall patient and graft survival rates in this category 
of patients[34]. HCV recurrence was reported to be 
more rapid in the group of patients who received anti-
HCV-positive grafts, although it did not reach statistical 
significance (P = 0.07)[34]. The authors suggested appro-
priate use of anti-HCV-positive donor grafts, especially 
if HCV-RNA is positive, as their use might be associated 
with more rapid fibrosis progression[34]. The recent 
introduction of direct antiviral agents for treatment of 
HCV infection will likely reshape this practice. 
Malignancies
According to the UNOS database, 2.7% of deceased 
donors have a history of cancer[35]. Between 2000 and 
2005, more than 800 LT procedures were performed 
using grafts from donors with a history of malignancy, 
and only two donors transmitted a fatal disease[35]. 
The most common cancers were non melanoma skin 
neoplasms followed by central nervous system malig-
nancies[35]. 
Melanoma is one of the most commonly reported 
donor-derived malignancies and might have one of the 
highest transmission rates and associated mortality 
if inadvertently transmitted to the recipient. As its 
biological behavior is complex and characterized by late 
recurrences (tumor dormancy) donors with an history of 
malignant melanoma should always be discarded also 
in case of cured disease[36]. Donors with central nervous 
system malignancies should be carefully evaluated 
as certain risk factors are associated with malignancy 
transmission; organs from donors having high grade (Ⅲ 
or Ⅳ) tumors, ventriculo-systemic shunts or history of 
extensive cranial surgery that disrupts the blood-brain 
barrier are associated with a transmission rate of 45% 
and should not be considered for transplantation; in cases 
where the underlying etiology of brain death is unclear, a 
rapid limited brain autopsy should be conducted[37].
Data derived from the United Kingdom Transplant 
Registry showed that 18 solid organ recipients developed 
cancer from 16 donors (0.06%): 3 were donor-derived 
cancer (0.01%) and 15 were donor-transmitted cancer 
(0.05%)[38]. Of the 15 donor-transmitted cancers, 6 
were renal; 5 were lung; 2 were lymphoma; 1 was 
neuroendocrine, and 1 colon cancer[38].
Some recent Italian series have shown no disease 
transmission with use of grafts from donors with low-
grade malignancies or neoplasms of low metastatic 
potential[39,40]. An accurate donor evaluation coupled 
with histological information of tumor grade allows to 
reduce to acceptable rates the risk of donor-to-recipient 
transmission[39,40]. Donors with a documented history 
of malignancy should not discarded per se, especially 
for low-grade central nervous system tumors and mali-
gnancies treated successfully with long-term disease-
free survival rates. However, there is still variability in 
guidelines and practices across countries[39,40]. 
Steatosis
Steatosis is a very common chronic liver disease and 
it is estimated to occur in more than 65% of obese 
patients[41]. Microvescicular steatosis is accumulation 
of small fatty droplets not displacing the cell nucleus, 
and even if diffuse it does not entail a higher risk 
for graft loss after LT[42]. Macrovescicular steatosis is 
characterized by large droplets displacing the nucleus 
to the cell periphery and is associated with a significant 
risk factor for PNF[42,43]. It can be classified based on the 
proportion of hepatocytes affected, being mild < 30%, 
moderate from 30% to 60%, and severe > 60%[43]. 
Most transplant centers do not use grafts with more than 
30% of macrovescicular steatosis. However, use of these 
latter grafts is suggested reducing cold storage within 6 
h[44]. Steatotic livers show heightened sensitivity to I/R 
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ALLOCATION STRATEGIES
In LT setting, several allocation policies have been 
proposed over the recent years, but none is complete in 
evaluating all clinical aspects of a liver disease patient. 
Patient based policies includes: Urgency principle 
and utility based principle. The urgency principle is 
based on MELD[60], and although widely practiced it 
has raised criticism over the years. The components 
of the formula are not always objective, due to inter-
laboratory variability[61]; symptom-based exceptions 
may be under- or mis-scored, and extra-points are 
assigned almost arbitrarily[62]. The first-come-first-served 
principle did not take into consideration the individual 
patient gravity with the resulting risk of increased 
death on the waitlist of sickest patients. The utility 
based principle is based on survival benefit concept 
and was introduced as a way to balancing the risk of 
death after LT with the risk of mortality while on the list, 
thus avoiding futile transplantation[63]; survival benefit 
computes the difference between the mean lifetime 
with and without LT so that a graft goes to the patient 
with the greatest difference between the predicted 
post transplant lifetime and the predicted waiting list 
lifetime for this specific donor. Donor-based policies 
were introduced with the increasing use of ECD, as 
graft and patient survival was greatly reduced for some 
unfavorable donor-to-recipient matching categories[64,65]. 
Feng et al[1] introduced the concept of a donor risk 
index (DRI) assessing donor variables that can affect 
transplant outcomes, thus providing formal assessment 
to clinical donor-related variables. Main limitations of 
DRI are: First DRI was reported before introduction of 
MELD, second DRI is mainly related to donor age, third 
DRI takes into consideration only data at the time of 
procurement. Combined donor-recipient based systems 
have been proposed widely; balance of risks (BAR) 
score includes: MELD, recipient age, retransplant, life 
support dependence prior to LT, donor age and CIT thus 
establishing a threshold at 18 points. BAR score is mainly 
determined by MELD balanced by other factors both of 
recipient and donor[66]. Actually the ideal matching is 
still a theory based more on myth than reality. To date, 




A recent study was conducted on 42869 first liver 
transplants performed in Europe with the use of either 
University of Wisconsin solution (UW; n = 24562), 
histidine-tryptophan-ketoglutarate (HTK; n = 8696), 
Celsior solution (CE; n = 7756) or the Institute Georges 
Lopez preservation solution (IGL-1; n = 1855)[67]. The 
overall 3-year graft survival was higher with UW, IGL-1 
and CE (75%, 75% and 73%, respectively), compared 
to HTK (69%) (P < 0.0001)[67]. The same trend was 
observed with a total ischemia time > 12 h or for grafts 
injury and several mechanisms have been proposed 
to explain this. The liver might be more subjected to 
lipid peroxidation[45], and a more accentuated pro-
inflammatory response with release of mediators, such 
as tumor necrosis factor (TNF)-α, and an increased 
neutrophil infiltration[46]. Animal models showed narrow-
ed and tortuous microvessels with reduced hepatic and 
sinusoidal blood flow, mitochondrial dysfunction and 
decreased energy levels[47]. 
INTERVENTIONS
Several approaches have been suggested in order to 
reduce the sensitivity of livers to I/R injury. Physical 
exercise and dietary interventions are reserved to living 
donors, but it may take long before providing histologic 
changes in liver cells[48]. Drug schedules have been 
used to decrease liver cell lipid intake. Urso-deoxy-
cholic acid was used in a clinical trial, but its results are 
controversial[49]. Pentoxifylline was used based on its 
effect on reducing TNF-α levels and increasing gluta-
thione activity[50]. To date, only bezafibrate was reported 
in steatotic living liver donors before transplantation[51]. 
Ischemic preconditioning is based on intermittent 
clamping before cold flushing and has been shown 
to reduce lipid peroxidation, hepatic microcirculation 
failure and neutrophil accumulation when applied to 
steatotic livers[52]. Volatile anesthesia has been shown 
to be superior to the intravenous one in preventing 
liver injury after reperfusion in previous studies on liver 
resection[53], but a recent multicenter trial comparing 
propofol with sevoflurane in LT has shown no difference 
in terms of acute organ injury and clinical outcomes 
between the two regimens[54].
Several experimental strategies can be applied to 
either the donor or the graft. Pharmacological precon-
ditioning was successfully used in rats with resulting 
reduced inflammatory responses, parenchymal dys-
function, and injury[55]. Heat-shock preconditioning is 
a method to induce endogenous protective heat-shock 
proteins by exposure to heat, and is applied 3-48 h 
before organ procurement[56]. This leads to a decrease in 
TNF-α, an increase in nitric monoxide and improvement 
of microcirculation and inhibited platelet aggregation[56]. 
Some pharmacological additives can be used during cold 
preservation to ameliorate metabolism and suppress 
inflammation, such as interleukin-6, pentoxifylline, 
L-carnitine, carvedilol, epidermal growth factor, and 
insulin like growth factor 1[57]. Venous systemic oxygen 
persufflation during static cold storage (SCS) preser-
vation was described in the Nineties to supply gaseous 
oxygen to livers, and it utes was demonstrated that 
application for 90 min may rescue steatotic livers after 
extended SCS preservation[58]. The use of machine 
perfusion has recently been introduced in some centers 
and may preserve steatotic livers by continuous supply of 
nutrients, removal of waste products, and maintenance 
of ideal microcirculation conditions[59].
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used for patients with cancer (P < 0.0001)[67]. 
Retrieval techniques
During liver procurement for deceased donation, rapid 
en bloc procurement with minimal manipulation after 
clamping the donor aorta achieved better early graft 
function post-transplantation[68].
In DCD, most surgeons use some modification of 
the super rapid recovery technique[69]. The donor is 
prepared as well as the surgical instruments. After the 
declaration of death the surgeons expeditiously perform 
aortic cannulation. Thereafter, the thoracic or supraceliac 
aorta is cross-clamped, and the vena cava is vented into 
the right chest. The portal system can be flushed by in 
situ cannulation of the inferior mesenteric vein or on the 
back table. Organs can be removed separately or en 
bloc. Cannulating the donor pre-mortem may decreases 
warm ischemia time[69]. It is necessary to cannulate 
both femoral artery and vein before support withdrawl 
in order to perfuse with cold preservative solution 
immediately after declaration of death. Thereafter, a 
median sternotomy and midline abdominal incisions are 
made and the intra-abdominal organs are topically ice 
cooled and then removed en bloc or separately[69]. 
In donors from brain death, a randomized pros-
pective study was performed to test the impact of the 
donor harvesting technique on post-transplantation 
outcomes in ECD. A modified double perfusion (MDP) 
technique was compared with the single aortic perfusion 
(SAP) technique. Thirty-five suboptimal grafts were 
randomly assigned to either technique (18 MDP livers 
vs 17 SAP livers). Variables were comparable in the 2 
study groups. The SAP group presented higher blood 
transaminases and bilirubin levels after LT. Graft primary 
dysfunction was also significantly higher (P = 0.01) in 
the SAP group (35%) vs the MDP group (5%). In the 
SAP group, 5 cases required re-LT (< 30 d). Patient 
and graft survival rates were higher in the MDP (100% 
in both cases) than in the SAP group (68% and 58%, 
respectively) so that the study was stopped[70].
Perfusion with fibrinolytic drugs
Plasminogen activators have been tested in LT to 
prevent microthrombosis, improve microcirculation 
and oxygen supply[71]. Liver grafts from non-heart-
beating donors (NHBD) are additionally affected by 
microvascular alterations, including erythrocyte aggre-
gation and thrombi formation, which might hamper 
appropriate equilibration of the preservation solution to 
the graft microvasculature[71]. Streptokinase was used 
in experimental models to observe post-preservation 
viability in NHBD. Streptokinase preflush resulted in 
a relevant and significant improvement of structural 
integrity as well as functional and metabolic recovery[71,72].
ITBL have a multifactorial origin but I/R injury 
and microthrombosis are considered to be the most 
relevant[73]. In order to decrease its incidence, urokinase 
perfusion has been tested[74]. In a prospective study by 
Lang R et al[74], the arterial system of the donor liver 
was perfused twice with urokinase during cold perfusion 
and after trimming of the donor liver. The incidence of 
ITBLs resulted lower than in the control group[74].
CIT
Prolonged CIT is an independent risk factor for DGF and 
PNF[75]. The European Liver Transplant Registry survey 
showed a lower 5-year survival rate with CIT over 15 h 
if compared with CIT less than 12 h[76]. Similar results 
were reported in a United States survey[77].
Liver grafts from elderly donors and/or donors with 
steatosis are even more affected by prolonged CIT, 
which should be kept below 8 h[78]. In our previous 
series, we showed that, albeit not statistically significant, 
graft survival was lower for grafts > 80 years with a CIT 
> 8 h (3-year survival 82.6% vs 61.9%, P = 0.078)[5].
Biopsy
Biopsy can be a valuable tool to determine the utility in 
pursuing donation in ECDs, particularly with liver-only 
donors[79]. Nevertheless, there are still no guidelines on 
its routine use in this kind of donors. In our previous 
experience, we performed on demand biopsies based 
on surgical evaluation at procurement and discarded 
livers in the presence of macrovescicular steatosis > 
30%, necrosis > 5%, fibrosis > 2% as per Ishak’s 
score, severe micro and macroangiopathy, and severe 
inflammation[5]. In a recent review some authors stated 
that pre-transplant histopathological evaluation is a time-
effective, accurate, and reliable tool to assess liver quality 
from candidate deceased donors[80]. Pre-transplant 
biopsies are of value in the selection of donor livers for 
transplantation, especially in case of ECD, and should be 
performed more frequently in order to avoid unnecessary 
loss of organs suitable for transplantation and trans-
plantation of inappropriate organs[80]. Correlation of 
histopathological findings with clinical conditions is 
essential and requires excellent communication between 
pathologists, surgeons, and the other members of the 
transplant team. 
Machine perfusion and machine preservation
Machine perfusion and/or preservation (PM) consists 
of a pump creating a flow of blood or preservative 
solution through the organ[81]. This continuous perfusion 
allows better preservation, oxygenation and removal 
of metabolites[81]. Another advantage is the possibility 
to monitor the performance of the graft and to provide 
adjuvant substances[81,82]. PM can be divided into 3 
groups based on the temperature of preservation: Hypo-
thermic (HMP) at 4 ℃; normothermic (NMP) at 37 ℃, 
and subnormothermic (SNMP) at 20 ℃-25 ℃. Different 
flow regimes and pressures (pulsatile vs unpulsatile), 
single (artery) vs dual perfusion (artery and portal vein), 
oxygenated vs nonoxygenated[82].
The HMP, by lowering the metabolism but providing 
metabolic substrates, is reported to protect grafts from 
ischemic insults related to reperfusion[83]. Guarrera et al[83] 
were the first to analyze the impact of this method in 
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humans observing an attenuation of biochemical markers 
of liver injury, less biliary complications and hospital stay. 
They concluded that HMP of donor livers provided safe 
and reliable preservation[83]. The addiction of oxygen to 
perfusion solution (hypothermic oxygenated perfusion) in 
animal models showed further improvements[84,85].
The SNMP lowers the liver metabolic demand in 
sub-physiological temperature conditions, however 
maintaining sufficient metabolism for viability testing 
and improvement of graft function[86,87]. In an animal 
model, a beneficial effect with lower transaminases 
was found, while rising total bilirubin levels suggested 
inadequate prevention of I/R or hypothermia-induced 
biliary damage[86].
This technique was tested on livers discarded from 
transplant and showed a preservation of liver function 
with minimal injury and an improvement in various 
post-ischemia hepatobiliary parameters[87].
The NMP system seems the most promising technique 
as it allows to maintain livers in an environment similar 
to human body with normal temperature and metabolite 
and oxygen supply[88]. Moreover, it allows to monitor 
liver function parameters such as pH, transaminases, 
and the bile output[88]. It has been recently tested on a 
human setting with optimal results showing favorable 
safety and feasibility profiles, whilst costs seems to limit 
its widespread applicability.
Back-table 
The major back table concerns using ECD are related 
to arterial structure and anatomy. When using grafts 
from old donors, arterial evaluation plays a pivotal 
role as aneurysms or severe atherosclerosis may led 
to graft discharge[5]. Graft arterial reconstruction of a 
right replaced hepatic artery using a safe and rigorous 
technique does not enhance the risk of arterial com-
plications or graft loss, and the technique using the GDA 
stump is to be recommended for routine use[89].
In order to reduce the incidence of ITBL, some authors 
reported on the use of back-table arterial pressure 
perfusion to achieve reliable perfusion of the capillary 
system of the biliary tract, which may be impaired by 
the high viscosity of UW solution[90]. A highly significant 
difference in the incidence of ITBL was found when 
this technique was used when compared to standard 
perfusion with lower peak AST and ALT levels[91]. The 
authors’ conclusion was that arterial back-table pressure 
perfusion is an easy and reliable method for preventing 
ischemic biliary lesions in LT and suggested it should be 
standard in liver procurement[90,91].
Split liver grafts
Split liver transplant (SLT) is a technique used to in-
crease the donor pool that creates two allografts from a 
single liver graft. Technical and logistical issues in both 
donors and recipients prevent its worldwide usage and it 
accounts for only 4% of LT in the United States. Splitting 
was originally performed as an ex-vivo bench procedure 
but it was after performed as an in-situ procedure as 
well in order to reduce CIT and prevent blood loss after 
reperfusion[92]. SLT in adults is associated with significant 
increase (10%) of graft failure and recipient morbidity. 
Results are notably better in children[93].
Even if procured from ideal donors these grafts 
should be considered as extended criteria as the volume 
is lower and may lead to hepatic failure in the post-
operative course. Moreover non-optimal positioning in 
the recipients may lead to compromised venous outflow 
and complications as biliary leakage, hepatic artery 
thrombosis (HAT), IPF are more frequent than in whole 
organ LT[94].
SLT for two adults has been performed reporting 
worst results with the left segment and is actually 
considered a high risk procedure due to insufficient 
parenchymal volume and complex vascular anasto-
mosis[94-96].
The use of left allografts should be primary considered 
for pediatric patients while the use of right allografts in 
adults marginally increases risks of graft failure so that 
SLT should be considered as a safe technique to expand 
the donor pool.
TRANSPLANTATION
At transplantation, the main strategies encompass the 
modality of graft reperfusion and use of temporary 
porto-caval shunts[97-100]. Graft reperfusion can be se-
quential or simultaneous. In the sequential mode, the 
liver graft is perfused first via portal vein or hepatic 
artery, while in the simultaneous technique the arterial 
anastomosis is fashioned during the anhepatic phase 
and both the porta and the hepatic artery are perfused 
simultaneously[97,98].
Sequential reperfusion is associated with a shorter 
CIT. However, if the porta is perfused first the delay of 
arterial revascularization is associated with more pro-
nounced microvascular disturbances, while if the hepatic 
artery is perfused first this might cause an increased 
blood flow called reactive hyperemia[98]. Simultaneous 
graft reperfusion results in improved oxygenation but 
may entail a longer CIT[97-99].
The use of temporary porto-caval shunt (TPCS) is 
controversial. The hemodynamic and immunological 
consequences of portal vein clamping are poorly chara-
cterized. In animal models an interruption of portal flow 
for up to 90 min induces edema of the gut with mucosal 
damages. The use of TPCS was initially advocated for 
patient with acute liver failure without collaterals. It was 
thought to be useless in cirrhotic patients as the presence 
of collaterals resulted in little hemodynamic changes 
during portal clamping.
In a prospective randomized trials Figueras et al[101] 
demonstrated a beneficial effect of TPCS in terms of 
decreased blood transfusions especially in patients with 
severe portal hypertension and high portal flow.
Renal impairment is a common sequel to LT. Impaired 
renal perfusion, vascular instability and the release of 
cytokines at reperfusion contribute to a reduction in renal 
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function[102].
In a study by Ghinolfi et al[100] it has been shown to 
improve hemodynamic stability and renal function in 
patients undergoing orthotopic LT. Lower graft survival 
rates were reported in patients of high DRI liver grafts 
when a TPCS was not used[100]. TPCS improves the peri-
operative outcome, this being more evident when high-
risk grafts are allocated to high-risk patients[100].
Another series by Pratschke et al[103] showed reduced 
hepatic injury and increased portal flow after reperfusion. 
Retransplantation rate was decreased and long term 




Biliary complications continue to be a major issue in LT 
ranging between 10% and 30%[104,105]. Anastomotic 
strictures (AS) are mainly related to the surgical tech-
nique and to ischemia to the distal bile stump[104,105]. Non-
AS (NAS) are thought to be caused by three different 
types of injuries: I/R, immune-mediated mechanisms, 
and cytotoxic injury from bile salts[106]. The highest 
incidence of NAS has been reported for DCD livers as 
they suffer from an additional warm ischemia time during 
organ retrieval[107]. NAS with a patent hepatic artery are 
generally referred to as ITBL. The incidence of ITBL in 
ECD is higher, due to a major vulnerability to I/R injury 
and to warm ischemia time and CIT, and are reported in 
up to 14% vs 3% for younger donors.
Several strategies have been suggested to reduce 
the incidence and severity of ITBL[108-111]. The relative 
importance of portal venous blood flow in developing 
ITBL was outlined by Farid et al[108] because these 
lesions were diagnosed in patients with a normal arterial 
flow but with portal thrombosis. In order to reduce the 
incidence of graft microangiopathy and thrombosis, 
back-table pressure arterial perfusion and the use 
of plasminogen activators have been proposed with 
favorable results. Simultaneous graft revascularization 
seems to be associated with a lower incidence of 
ITBL than sequential revascularization[109,110]. Viscous 
preservation solutions may negatively impact on efficacy 
of flushing of the bile ducts capillaries, resulting in 
residual bile crystallization and obstruction[111-113]. Use 
of less viscous solutions, like HTK, seems to provide 
better results in reducing the incidence of biliary tract 
injuries, despite the recent results of the European liver 
transplant registry data[67,112].
In a large study, a CIT > 10 h was found to be 
associated with a higher incidence of ITBL and every 
effort should be made not to exceed this limit[113].
Vascular complications
HAT represents more than 50% of all arterial com-
plications following LT and it is divided into early (< 4 
wk from LT) and late HAT (> 4 wk from LT)[114-116]. Early 
HAT is generally related to technical problems and can 
have serious consequences[115]. Emergent interven-
tions are usually needed with early HAT because of its 
related ischemia/necrosis of the bile duct system[114]. 
Although urgent re-transplantation is considered the 
main treatment for early HAT, endovascular interventions 
including percutaneous transluminal angioplasty (PTA), 
intra-arterial thrombolysis (IAT) in selective cases, and 
stent placement may be alternative treatments[117,118]. 
Currently many centers consider interventional radiology 
as first choice for the management of early HAT[118,119]. 
IAT can be considered but is related to high risk of 
hemorrhage in patients with recent (< 2 wk) surgery[120]. 
Late HAT can be silent in up to 50% of patients with 
only mildly elevated liver function tests[116]. Symptomatic 
patients often present with biliary complications with 
recurrent cholangitis, abscess and biliary leakage or 
stricture, and the presentation may be insidious[116]. 
Late HAT is usually due to ischemic or immunologic 
injuries and can be treated with biliary stenting and/or 
endovascular interventions[116,117].
Hepatic artery stenosis (HAS) has been treated 
both with PTA and stent placement with comparable 
results[117-120]. The use of PTA for HAS can reduce the rate 
of HAT[120]. Solitary stenosis are usually treated with PTA 
while angioplasty is used for tandem lesions[117-120]. These 
procedures are related to complications and risks that 
have to be taken into consideration and moreover are, in 
some cases, ineffective so that surgical intervention such 
as anastomotic reconstruction or re-transplantation must 
be applied[120].
Aneurysms and pseudoaneurysms of the hepatic 
artery are very rare complications after LT, but they 
are associated with high mortality rates (> 50%)[121]. 
Both can be treated by either surgical or endovascular 
procedures[121].
A series from the UNOS database reported that the 
risk of HAT with loss of the graft increases progressively 
with each decade of donor age > 50 years, such that 
a 61% risk was associated with use of donors older 
than 70 years[122]. A recent experience with donors 
older than 70 years showed a lower incidence of HAT 
(4.7%) and improved results were attributed to better 
management[123]. Ghinolfi et al[5] in their series showed 
a 3.6% of severe vascular complications: 10 (1.2%) 
HAT and 7 HAS (0.8%) with no differences across all 
donor age groups. There were no differences in terms of 
donor age for the 11 (1.3%) cases of portal thrombosis 
as well[5].
Venous complications are more frequent in LDLT[124]. 
Compared with the arterial complications, venous 
adverse events usually have a better response rate to 
endovascular interventions, such as angioplasty or stent 
placement[124,125]. Endovascular procedures are consi-
dered as the first choice for post-transplant portal vein 
complications with high success rates[125]. 
CONCLUSION
The imbalance between the number of potential 
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recipients and available donors still represents a major 
concern in LT so that the expansion of donor pool 
continues to be a priority.
Improvements have been made in order to better 
define ECD but many lacks still exist regarding their 
use. Some centers routinely use ECD but their results 
seem to be related more to their practical experience 
and can be reproduced with difficulties.
Some ethical considerations should also be carried 
out; the use of ECD can constitute a risk for recipients 
in terms of PNF, DGF and surgical complications so 
that some authors advocate the use of an informed 
consent about allograft specific risks. Moreover some 
combinations such as ECD with HCV recipients have 
been proved to be dangerous in terms of recurrence 
and survival but they have never been clearly censored 
by the scientific community.
It has finally to be taken into consideration that this 
is an expanding field in LT so that applying too strict 
rules on ECD use may preclude further advancement. 
Many efforts should be carried out in order to establish 
an international consensus on ECD use and to create 
guidelines that could be largely adopted. 
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